Clinical Trials Browser

OTHER × Pathologic Complete Response × Other hematologic neoplasm × Clear all

NCT04314219 2025-03-13

PTCy-PMAT

Phase 3 Recruiting

LymphoidOther hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01686334 2024-03-12

WIDEA

Phase 2 Active not recruiting

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT06180863 2023-12-26

Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients

Phase 2 Withdrawn

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT01656252 2020-11-03

PrE0901

Phase 1/2 Terminated

15 enrolled 5 charts

Classical hematologyOther hematologic neoplasm

Jacobs syndrome, Pathologic Complete Response, Leukemia, Thrombocytopenia, Leukemia, Myeloid, Acute

NCT03417427 2020-04-27

A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML

Phase 2 Unknown

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Leukemia, Myeloid, Acute

NCT01471067 2017-04-28

Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies

Phase 1 Completed

LymphoidMyeloidOther hematologic neoplasm

Pathologic Complete Response, Histiocytosis, Langerhans-Cell, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Philadelphia Chromosome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01843179 2017-02-17

Sulindac for Patients With AML

Phase 2 Withdrawn

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute